Zypadhera ® (olanzapin)

För fullständig produktresumé för Zypadhera® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

ZypAdhera® (olanzapinpamoat): Övergång från oral olanzapin

För att etablera tolerabilitet och effekt på olanzapinpamoat skall patienten initialt behandlas med oral olanzapin innan administrering av olanzapinpamoat. Den första dosen av olanzapinpamoat avgörs baserat på måldosen för oral olanzapin.

SE_cFAQ_OLZLA306_Y7_SWITCHING_FROM_ORAL_OLANZAPINE
SE_cFAQ_OLZLA306_Y7_SWITCHING_FROM_ORAL_OLANZAPINE
en-GB

Posology

In order to identify the first olanzapine pamoate dose for all patients, the scheme in Recommended dose scheme between oral olanzapine and olanzapine pamoate should be considered.1

Recommended dose scheme between oral olanzapine and olanzapine pamoate1

Target oral olanzapine dose

Recommended starting dose of olanzapine pamoate

Maintenance dose after 2 month of olanzapine pamoate treatment

10 mg/day

210 mg/2 weeks
or 405 mg/4 weeks

150 mg/2 weeks
or 300 mg/4 weeks

15 mg/day

300 mg/2 weeks

210 mg/2 weeks
or 405 mg/4 weeks

20 mg/day

300 mg/2 weeks

300 mg/2 weeks

Some specific patient populations may require lower starting doses and cautious dose escalation.2 For full information please refer to the summary of product characteristics.

Dose adjustment

Olanzapine LAI provides therapeutic levels of systemic olanzapine from the very first injection. However, approximately 3 months are needed to re-establish steady state.2

Patients should be monitored carefully for signs of relapse during the first one to two months of treatment.1

During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored during this period.1

During treatment, dose may subsequently be adjusted on the basis of individual clinical status. After clinical reassessment, dose may be adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks (Recommended dose scheme between oral olanzapine and olanzapine pamoate).1

Some specific patient populations may require lower starting doses and cautious dose escalation.2 For full information please refer to the summary of product characteristics.

Oral supplementation

If oral olanzapine supplementation is clinically indicated, then the combined total dose of olanzapine from both formulations should not exceed the corresponding maximum oral olanzapine dose of 20 mg/day.1

Important notes

Olanzapine pamoate is intended for deep gluteal intramuscular injection only.2

ZypAdhera 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection must not be confused with olanzapine 10 mg powder for solution for injection.1

References

1ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Datum fӧr senaste ӧversyn 2019 M05 01


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss